NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

MEDIBIO LIMITED (MEB)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 FROMTO
TRIVARX LTD16/10/2023
MEDIBIO LIMITED01/12/201416/10/2023
BIOPROSPECT LIMITED01/12/2014

Shareholder links

Our website ranking of MEB: rating 4
(4 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Computershare Brisbane
Level 1, 200 Mary Street Brisbane QLD 4000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 7 3229 9860
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000MEB8
Address:  647 Beaufort Street, Mt Lawley WA 6050
Tel:  +61 8 6189 1155Fax: +613 9077 9233

Date first listed: 29/01/2001
Company Secretary: Stephen Buckley
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Development of diagnostic heart rate variability technology for mental health diagnosis

News & Events

Expand this box to read and print

name changed to TrivarX Ltd

16/10/2023

The suspension of trading in the securities of Medibio Limited will be lifted immediately following the release by MEB of an announcement regarding a capital raising.

22/06/2022

Commitments received for $1.4 million placement at $0.0015 (0.15 cents) per fully paid ordinary share. Issue price of $0.0015 (0.15 cents). Placement to be completed over two tranches. Investors under the placement to be offered one (1) free attaching option for every one (1) new share subscribed for, exercisable at $0.004 (0.4 cents) on or before an expiry date of 15 June 2027. Issue of securities under Tranche 2 are subject to shareholder approval, to be sought at an EGM to be held in August 2022.

22/06/2022

The Company now expects to make an announcement in relation to the capital raising before the commencement of trading on 21 June 2022 and confirms its request that the suspension will continue until the announcement is made.

20/06/2022

The securities of Medibio Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEB, pending the release of an announcement regarding a capital raising.

16/06/2022

The suspension of trading in the securities of Medibio Limited will be lifted immediately following the release by MEB of an announcement regarding its capital raising.

10/07/2019

Commitments were received for $3.5 million placement at $0.01 per fully paid ordinary share. SPP were on the same terms, underwritten for $520,000. Issue price of $0.01, a 51.6% discount to the 5-day VWAP. Placement to be completed over two stages. ✓ Investors under the placement and Eligible shareholders under the SPP to be offered 1 free attaching option for each new share subscribed for, exercisable at $0.03 until an expiry date of 1 December 2021 and for which the Company will seek quotation on the ASX. Existing holders of convertible notes have agreed to early conversion of their notes for fully paid ordinary shares at a conversion price equal to the issue price under the Placement. Each noteholder will be offered 1 free New Option for each Share issued. Issue of securities under Stage 2 of the Placement, the SPP (including underwritten shortfall) and the early conversion of notes is subject to shareholder approval, to be sought at an EGM to be held in late August 2019.

10/07/2019

The securities of Medibio Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEB, pending the release of an announcement regarding a capital raising.

09/07/2019

we understand that on or about this date the company consolidated its shares 1 for 100

20/03/2015

The suspension of trading in the securities of Medibio Limited (the "Company") will be lifted immediately following receipt of an announcement in relation to an agreement with John Hopkins Hospital. Security Code: MEB

01/12/2014

name changed from Bioprospect Limited - was previously called MEDIA ASIA PACIFIC LIMITED which delisted from ASX on 31 August 1998 following the company's failure to lodge annual listing fees in respect of the year ended 30/06/99.

01/12/2014

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    09/11/2018Chris Indermaur200,000$0.040$8,000
    06/11/2018Andrew Maxwell216,002$0.044$9,434
    02/08/2017Andrew Maxwell26,000$0.380$9,880
    10/07/2017Peter Carlisle5,500$0.373$2,053
    18/04/2017Jack Cosentino100,000$0.370$37,000

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    David TrimboliNon Exec Chairman25/08/2022
    Steve SathreCFO01/01/2019
    Lisa HeineNon Exec Director29/08/2019
    Thomas R. YoungNon Exec Director19/09/2022
    Lisa IdeNon Exec Director29/08/2019
    Chris NtoumenopoulosNon Exec Director15/02/2023
    Liwanag OjalaNon Exec Director29/08/2019

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Melanie LeydinNon Exec Director22/02/201912/04/2023
    Matt MesnikNon Exec Director02/03/202216/03/2023
    Stephen MitchleyNon Exec Director17/02/202211/11/2022
    Claude SolitarioManaging Director, CEO29/04/201422/06/2022
    Peter CarlisleIndependent Director05/06/201710/06/2022
    David KaysenChairman, CEO02/11/201808/01/2020
    Patrick KennedyNon Exec Director04/07/201729/08/2019
    Franklyn PrendergastNon Exec Director27/01/201629/08/2019
    Michael PhelpsNon Exec Director05/06/201729/08/2019
    Andrew MaxwellNon Exec Director01/02/201722/02/2019
    Brian MowerCFO24/04/201701/01/2019
    Chris IndermaurNon Exec Chairman02/04/201531/12/2018
    Jack CosentinoManaging Director, CEO16/02/201728/08/2018
    Adam DarkinsDeputy Chairman, Non Exec Director19/07/201719/01/2018
    Kris KnauerExecutive Director, CFO02/07/201413/10/2017
    Robert LeesCFO28/09/201224/04/2017
    James CampbellNon Exec Director07/09/201430/09/2016
    Vince FayadNon Exec Chairman29/04/201407/04/2015
    Silvi ElkhouriNon Exec Director15/11/201308/09/2014
    Claude SolitarioExecutive Director29/04/201408/09/2014
    Peter MayNon Exec Director01/11/200830/06/2014
    Benjamin CooperExecutive Director10/04/201229/04/2014
    Winton WilleseeChairman, Non Exec Director16/09/201115/11/2013
    Peter PellegrinoManaging Director01/11/200919/11/2012
    Colin JohnstonCFO01/03/200428/09/2012
    Jacob KhouriNon Exec Director16/02/201118/09/2012

    Date of first appointment, title may have changed.